Nothing Special   »   [go: up one dir, main page]

WO2002022175A3 - Method and composition for treating tumors by selective induction of apoptosis - Google Patents

Method and composition for treating tumors by selective induction of apoptosis Download PDF

Info

Publication number
WO2002022175A3
WO2002022175A3 PCT/US2001/028259 US0128259W WO0222175A3 WO 2002022175 A3 WO2002022175 A3 WO 2002022175A3 US 0128259 W US0128259 W US 0128259W WO 0222175 A3 WO0222175 A3 WO 0222175A3
Authority
WO
WIPO (PCT)
Prior art keywords
trail
cells
receptor
express
expression vector
Prior art date
Application number
PCT/US2001/028259
Other languages
French (fr)
Other versions
WO2002022175A2 (en
Inventor
Jian-Yun Dong
James S Norris
Original Assignee
Musc Found For Res Dev
Jian-Yun Dong
James S Norris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev, Jian-Yun Dong, James S Norris filed Critical Musc Found For Res Dev
Priority to AU2001290720A priority Critical patent/AU2001290720A1/en
Priority to CA002421585A priority patent/CA2421585A1/en
Priority to JP2002526423A priority patent/JP2004526666A/en
Priority to EP01970744A priority patent/EP1317288A2/en
Publication of WO2002022175A2 publication Critical patent/WO2002022175A2/en
Publication of WO2002022175A3 publication Critical patent/WO2002022175A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions and methods are provided for inducing death of cancer cells through apotposis mediated by the death ligand, TRAIL. The method comprising: introducing an expression vector into a group of cells comprising cells that express a receptor for TRAIL. The expression vector comprises a polynucleotide sequence encoding TRAIL whose expression is preferably regulated by a conditional promoter in the vector. The cells into which the expression vector is introduced express TRAIL when conditions are suitable to activate the conditional promoter. The expressed TRAIL induces cell death in those cells which express the TRAIL receptor through interaction between TRAIL and the receptor such as DR4 and DR5. The method can be used for treating tumors site-specifically and in a dose-adjustable manner.
PCT/US2001/028259 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis WO2002022175A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001290720A AU2001290720A1 (en) 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis
CA002421585A CA2421585A1 (en) 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis
JP2002526423A JP2004526666A (en) 2000-09-11 2001-09-10 Compositions and methods for treating tumors by selective induction of apoptosis
EP01970744A EP1317288A2 (en) 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65877900A 2000-09-11 2000-09-11
US09/658,779 2000-09-11

Publications (2)

Publication Number Publication Date
WO2002022175A2 WO2002022175A2 (en) 2002-03-21
WO2002022175A3 true WO2002022175A3 (en) 2002-08-08

Family

ID=24642656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/028259 WO2002022175A2 (en) 2000-09-11 2001-09-10 Method and composition for treating tumors by selective induction of apoptosis

Country Status (6)

Country Link
EP (1) EP1317288A2 (en)
JP (1) JP2004526666A (en)
CN (1) CN1744919A (en)
AU (1) AU2001290720A1 (en)
CA (1) CA2421585A1 (en)
WO (1) WO2002022175A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1621550A1 (en) * 2004-07-29 2006-02-01 Dompé S.P.A. Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
CA2585645C (en) 2004-10-29 2014-10-21 Musc Foundation For Research Development Ceramides and apoptosis-signaling ligand
US8093393B2 (en) 2004-10-29 2012-01-10 Musc Foundation For Research Development Cationic ceramides, and analogs thereof, and their use for preventing or treating cancer
CN101144081B (en) * 2006-09-14 2011-06-22 复旦大学 Nucleic acid molecule TRAIL and application in preparation of anti-tumour pharmaceutical
JP5721631B2 (en) 2008-11-06 2015-05-20 ムスク ファウンデーション フォー リサーチ デベロップメント Lysosomal affinity inhibitors of acid ceramidase
AU2010316996A1 (en) * 2009-11-05 2012-06-14 Proyecto De Biomedicina Cima, S.L. Regulated expression systems
US8703732B2 (en) * 2010-04-01 2014-04-22 Korea Research Institute Of Bioscience And Biotech Composition for enhancing TRAIL sensitivity comprising inhibitors for expression or activity of TIP41 as a target gene of TRAIL sensitizer
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
US9862932B2 (en) 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
WO2014035474A1 (en) 2012-08-30 2014-03-06 The General Hospital Corporation Compositions and methods for treating cancer
EA036275B1 (en) 2013-06-25 2020-10-21 Дзе Уолтер Энд Элиза Хол Инститьют Оф Медикал Рисерч Method of treating intracellular infection
CN105126120B (en) * 2015-08-24 2018-12-21 浙江大学 Long non-coding RNA H19 and cancer platinum-based chemotherapy Drug-resistant correlation
CN109689873A (en) * 2016-06-03 2019-04-26 国家农艺研究院 The diet controlled expression of the nucleic acid of encoding pro-apoptosis proteins
US20200248149A1 (en) * 2017-03-24 2020-08-06 Ohio State Innovation Foundation Novel recombinant adeno-associated viral vectors restricting off-target transduction in liver and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079495A1 (en) * 2000-04-12 2001-10-25 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/apo-2 ligand gene transfer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079495A1 (en) * 2000-04-12 2001-10-25 University Of Iowa Research Foundation Method of inducing tumor cell apoptosis using trail/apo-2 ligand gene transfer

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
CELL DEATH AND DIFFERENTIATION, vol. 6, no. 2, February 1999 (1999-02-01), pages 175 - 182, ISSN: 1350-9047 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; April 1998 (1998-04-01), LARREGINA A T ET AL: "FasL induces Fas/Apo1-mediated apoptosis in human embyronic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors.", XP002196492, Database accession no. PREV199800256744 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 1999 (1999-02-01), HEDLUND TAMMY E ET AL: "Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells.", XP002196491, Database accession no. PREV199900167152 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 2000 (2000-05-01), RUBINCHIK S ET AL: "Adenoviral vector which delivers FasL-GFP fusion protein regulated by the tet-inducible expression system.", XP002196490, Database accession no. PREV200000281947 *
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; WEI X.-C. ET AL: "Killing effect of TNF - related apoptosis inducing ligand regulated by tetracycline on gastric cancer cell line NCI-N87.", XP002196489, retrieved from STN Database accession no. 2001300249 *
GENE THERAPY, vol. 5, no. 4, April 1998 (1998-04-01), pages 563 - 568, ISSN: 0969-7128 *
GENE THERAPY, vol. 7, no. 10, May 2000 (2000-05-01), pages 875 - 885, ISSN: 0969-7128 *
GRIFFITH T S ET AL: "Adenoviral-mediated gene transfer of TRAIL induces tumor cell apoptosis", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A1003, XP002176065, ISSN: 0892-6638 *
GRIFFITH T S ET AL: "ADENOVIRAL-MEDIATED TRANSFER OF THE TNF-RELATED APOPTOSIS-INDUCING LIGAND/APO-2 LIGAND GENE INDUCES TUMOR CELL APOPTOSIS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 165, 1 September 2000 (2000-09-01), pages 2886 - 2894, XP002176066, ISSN: 0022-1767 *
GURA ET AL: "HOW TRAIL KILLS CANCER CELLS, BUT NOT NORMAL CELLS", SCIENCE, vol. 77, 1997, pages 768, XP002196487 *
KAGAWA SHUNSUKE ET AL: "Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene.", CANCER RESEARCH, vol. 61, no. 8, 15 April 2001 (2001-04-15), pages 3330 - 3338, XP002196485, ISSN: 0008-5472 *
MANO TOSHIAKI ET AL: "Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions.", HUMAN GENE THERAPY, vol. 11, no. 12, 10 August 2000 (2000-08-10), pages 1625 - 1635, XP002196486, ISSN: 1043-0342 *
MORELLI A E ET AL: "NEURONAL AND GLIAL CELL TYPE-SPECIFIC PROMOTERS WITHIN ADENOVIRUS RECONBINANTS RESTRICT THE EXPRESSION OF THE APOPTOSIS-INDUCING MOLECULE FAS LIGAND TO PREDETERMINED BRAIN CELL TYPES, AND ABOLISH PERIPHERAL LIVER TOXICITY", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, READING, GB, vol. 80, 1999, pages 571 - 583, XP002936209, ISSN: 0022-1317 *
ROTH W ET AL: "TODESLIGANDEN/TODESREZEPTOREN ALS ANGRIFFSPUNKT DER SOMATISCHEN GENTHERAPIE MALIGNER GLOME", NEUROFORUM, SPEKTRUM AKAD. VERLAG, HEIDELBERG, DE, vol. 5, no. 3, 1999, pages 87 - 92, XP001016223, ISSN: 0947-0875 *
SGAGIAS MAGDALENE K ET AL: "Induction of apoptosis by adenovirus-mediated over-expression of BRCA1 in T47D human breast cancer cells.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 537, XP002196488, ISSN: 0197-016X *
WORLD JOURNAL OF GASTROENTEROLOGY, (2001) 7/4 (559-562). *

Also Published As

Publication number Publication date
WO2002022175A2 (en) 2002-03-21
CN1744919A (en) 2006-03-08
JP2004526666A (en) 2004-09-02
CA2421585A1 (en) 2002-03-21
AU2001290720A1 (en) 2002-03-26
EP1317288A2 (en) 2003-06-11

Similar Documents

Publication Publication Date Title
WO2002022175A3 (en) Method and composition for treating tumors by selective induction of apoptosis
IL193752A0 (en) Apo-2 ligand antibodies and hybridoma cell lines which produce them
IL193886A (en) Antibodies that bind to ldcam sequences
HK1034287A1 (en) Recombinational cloning using nucleic acids havingrecombination sites
IL138937A0 (en) Lineage specific cells, progenitor cells and methods for generating the same
GB9308271D0 (en) Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
WO2005042029A3 (en) Psma formulations and uses thereof
MXPA02009843A (en) T2r taste receptors and genes encoding same.
HK1032603A1 (en) Apo-2 ligand
NO20001684L (en) Methods and compositions to induce tumor-specific cytotoxicity
EP1077599A4 (en) PARTICLE BOMBARDMENT TRANSFORMATION OF $i(BRASSICA)
Lennox Lough Ennell: laboratory studies on sediment phosphorus release under varying mixing, aerobic and anaerobic conditions
Kang et al. The tectonic evolution from the archean to triassic in the north central gyeonggi massif (hongcheon-chuncheon areas) in the Korean peninsula, and its application to the tectonic evolution of the North China craton
EP1465912A4 (en) Novel chimeric tnf ligands
ZA985781B (en) Methods for using compositions containing dichlorophenyl imidazoldioxolan to treat seborrheic dermatitis, dandruff, psoriasis, and acne, and compositions thereof.
MX9606559A (en) Cancer therapy using lymphotoxin.
Zhai et al. SHRIMP Zircon U-Pb dating of the Hetai gold deposit in Western Guangdong, China and geological implications
Smith Jr Primary productivity of a Phaeocystis bloom in the Greenland Sea during spring, 1989
Misawa et al. Generation of intensity covariations of the oxygen green and red lines in the nightglow.
Maddox Transgenic route runs into sand
Chu et al. Axial ratio distribution effect of isolated microspheroids on the surface enhanced Raman scattering
WO2001088546A3 (en) Treatments and markers for cancers of the central nervous system
林昱 RESEARCH ON RED TIDE OCCURRENCES USING ENCLOSED EXPERIMANTAL ECOSYSTEMS IN WEST XIAMEN HARBOR, CHINA——RELATIONSHIP BETWEEN VARIOUS FACTORS AND RED TIDE OCCURRENCES
Liu et al. Experimental Study on the Leaching of Gold from Greenstone1
Seiberl The transformations of the gravitational and magnetic fields of the eastern Alpine region

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2421585

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001970744

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002526423

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001290720

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 018173152

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001970744

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001970744

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)